CTLT Stock Recent News
CTLT LATEST HEADLINES
Investors interested in stocks from the Medical - Drugs sector have probably already heard of Takeda Pharmaceutical Co. (TAK) and Catalent (CTLT). But which of these two stocks is more attractive to value investors?
Catalent (CTLT) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Catalent said on Friday it was unable to file its annual report with regulators on time as it requires additional time to complete "certain processes".
Catalent (CTLT) came out with quarterly earnings of $0.65 per share, beating the Zacks Consensus Estimate of $0.46 per share. This compares to earnings of $0.09 per share a year ago.
Contract drug manufacturer Catalent beat analysts' estimates for fourth-quarter revenue on Thursday, helped by its biologics segment that develops and manufactures cell and gene therapies.
Investors with an interest in Medical - Drugs stocks have likely encountered both Jazz Pharmaceuticals (JAZZ) and Catalent (CTLT). But which of these two companies is the best option for those looking for undervalued stocks?
Investors interested in Medical - Drugs stocks are likely familiar with United Therapeutics (UTHR) and Catalent (CTLT). But which of these two companies is the best option for those looking for undervalued stocks?
Catalent's (CTLT) latest capability expansion is expected to boost its business in the global clinical trials space in its Clinical Development & Supply network.
Investors with an interest in Medical - Drugs stocks have likely encountered both United Therapeutics (UTHR) and Catalent (CTLT). But which of these two stocks offers value investors a better bang for their buck right now?
SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced it has completed expansion of its clinical supply facility in Schorndorf, Germany. The Schorndorf site, Catalent's flagship European facility, provides comprehensive clinical supply services, including packaging, storage and distribution. The expansion increases the site's footprint by 32,000 square feet (3,000 square meters.